Fig. 3

Comparison of neutralisation titres against prototype, total, XBB.1, JN.1, and KP.2 variants among booster participants. Comparison of neutralisation titres (a) before and after dynamic zero control measures, (c) in those aged < 35 years and > 35 years, (b) in those with BMI 18.5–23.9 and BMI < 18.5 or > 23.9, and (d) in those who received homologous-type and heterologous-type boosters.